This special series on “Oligoprogressive Disease in Cancer” is edited by Dr. Michael T. Milano from the University of Rochester Medical Center, Rochester, NY, USA; Dr. Tithi Biswas, University of Florida, Gainesville, FL, USA; Dr. Charles B. Simone II from New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY, USA; and Dr. Simon S. Lo the University of Washington School of Medicine, Seattle, WA, USA.
Michael T. Milano, MD, PhD
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
Dr. Milano is a Professor of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. Dr. Milano's practice focuses on the care of patients with primary brain tumors, brain metastases, spine tumors, benign intracranial tumors (such as pituitary tumors, acoustic neuromas and meningiomas) and trigeminal neuralgia. Dr. Milano also treats patients with lung cancer and other thoracic tumors, head and neck cancer and metastatic cancer. He is involved in clinical research in all of these areas.
Dr. Milano is a board certified Radiation Oncologist. His undergraduate training was at the University of Notre Dame. His medical school, graduate school and internship training were at the University of Rochester. He received his residency training in Radiation Oncology at the University of Chicago. In 2005, he returned to Rochester to become a faculty member at University of Rochester's internationally recognized Department of Radiation Oncology. Dr. Milano has clinical expertise in stereotactic radiosurgery (SRS), stereotactic body (including spine) radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), and image guided radiation therapy (IGRT) and tomotherapy.
Tithi Biswas, MD
Department of Radiation Oncology, University of Florida, Gainesville, FL, USA
Dr. Biswas is a professor at the University of Florida and a radiation oncologist with UF Health. She earned my medical degree in 1996 from the Postgraduate Institute of Medical Education and Research in Chandigarh, India, and completed my residency in radiation oncology at the University of Rochester in New York in 2008.
In 2013, she was honored as Educator of the Year by the Association of Residents in Radiation Oncology. She also received the Pam Davis Senior Achievement and Professional Development Award from the Women Faculty of the CWRU School of Medicine in 2023. Additionally, I was named a Top Radiation Oncology Doctor in Cleveland by Top Doctor Magazine from 2019 to 2021.
She strives to serve her patients with empathy and compassion, treating each one as if they were a member of her own family.
Charles B. Simone II, MD, FASTRO, FACRO
New York Proton Center, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA
Charles B. Simone, II, MD, FACRO is Research Professor and Chief Medical Officer of the New York Proton Center and Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in the use of proton therapy, reirradiation, and stereotactic body radiation therapy, and in the development of innovative clinical trial strategies in thoracic oncology.
Prior to coming to NYPC, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at University of Pennsylvania and residency in radiation oncology at the National Cancer Institute (NCI), NIH, where he served as chief resident.
Dr. Simone is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who has published >600 scientific articles and chapters, given >525 scientific lectures to national/international audiences, and is the national Principal Investigator or Co-Chair of 8 NIH-funded cooperative group trials (5 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time Association of Residents in Radiation Oncology Educator of the Year Award winner. Dr. Simone is the Proton Collaborative Group (PCG) Board President. He Chairs the American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee, ASTRO Blue Ribbon Lung Panel, NRG Oncology Particle Therapy Work Group, PCG Lung Committee, American Radium Society (ARS) Appropriate Use Criteria Thoracic Committee, Particle Therapy Co-Operative Group (PTCOG) Thoracic Subcommittee, American College of Radiation Oncology (ACRO) Scientific Program Committee, NCI/Radiosurgery Society GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group, Varian FlashForward Consortium Scientific Committee, and Varian Proton Connect Users Group. He is Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Frontiers in Oncology, Translational Lung Cancer Research, Cancers, Journal of Thoracic Disease, Annals of Translational Medicine, Therapeutic Radiology and Oncology, Shanghai Chest, Journal of Xiangya Medicine, and AME Medical Journal.
Simon S. Lo, MB, ChB, FACR, FASTRO
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA
Dr. Simon S. Lo is Professor of Radiation Oncology, Professor of Neurological Surgery and Director of Stereotactic Body Radiation Therapy at the University of Washington School of Medicine in Seattle, WA. Dr. Lo is an expert in brain and spinal tumors, kidney cancer, metastatic disease, stereotactic radiosurgery and stereotactic body radiotherapy (SBRT). He is also the Past President of CARROS (Radiation Oncology Chapter) and an Assistant Councilor (on behalf of the American Radium Society) of the American College of Radiology (ACR). Dr. Lo is also a member of the Board of Directors and the Medical Director of the Distinction in Practice in SRS/ SBRT of the Radiosurgery Society. In 2019, he received the Lifetime Achievement Award from Society for Palliative Radiation Oncology.
He has published over 275 peer-reviewed papers, over 50 book chapters and 8 textbooks, including a comprehensive textbook in SBRT (>50,000 downloads), in addition to an adult CNS radiation oncology textbook (>85,000 downloads). He has given lectures on SBRT at the American Society for Radiation Oncology (ASTRO), Radiological Society of North America (RSNA), Radiosurgery Society (RSS), ESTRO, International Stereotactic Radiosurgery Society (ISRS), and American Thoracic Society (ATS) conferences and at multiple US and international academic centers. He is on the editorial boards of multiple oncology journals including Neurosurgery and Advances in Radiation Oncology and also a reviewer for Lancet, Lancet Oncol, Nature Reviews Clinical Oncol, JCO, Radiotherapy & Oncol, and IJROBP.
His research areas are palliative radiation oncology, CNS tumors, stereotactic radiosurgery, radiobiological modeling for ablative radiotherapy, SBRT for lung, liver, and spinal tumors, and toxicities associated with SBRT. He is a Fellow of the American College of Radiology and the American Society for Radiation Oncology (ASTRO).
Series Outline
- Introduction and History of Oligoprogressio
- What is oligoprogression
- Patient selection and the role of biomarkers in oligoprogression
- Oligoprogression in renal cell carcinoma
- Oligoprogression in lung cancer
- Oligoprogression in prostate cancer
- Oligoprogression in gynecologic cancer
- Oligoprogression in colorectal and other gastrointestinal cancers
- Oligoprogression in pediatric cancer
- Oligoprogression in breast cancer
- Current clinical trial landscape in oligoprogressive disease
Disclosure:
The series “Oligoprogressive Disease in Cancer” was commissioned by the editorial office, Annals of Palliative Medicine without any sponsorship or funding. Michael Milano, Tithi Biswas, Charles Simone III and Simon Lo are serving as the unpaid Guest Editors for the series.